- Ensysce Biosciences (ENSC, Financial) secures $2.2 million in gross proceeds through warrant exercise.
- New warrants issued allow purchase of 1,260,752 shares at an exercise price of $1.90.
- The funds will support the development of TAAP™ and MPAR® programs and enhance working capital.
Ensysce Biosciences, Inc. (ENSC), a clinical-stage pharmaceutical company specializing in innovative pain management solutions, has announced the successful closing of its warrant exercise transaction, securing approximately $2.2 million in gross proceeds. The transaction involved the exercise of warrants to purchase 630,376 shares at $3.24 per share, originally issued in March 2025.
In connection with this exercise, Ensysce issued new unregistered warrants for an aggregate of up to 1,260,752 shares at a reduced exercise price of $1.90 per share. These newly issued warrants are divided equally between 18-month and 5-year terms, presenting potential future capital opportunities.
The company plans to allocate the net proceeds from this transaction to further the development of its proprietary TAAP™ (Trypsin-Activated Abuse Protection) and MPAR® (Multi-Pill Abuse Resistance) programs. These initiatives aim to address the critical need for effective pain management solutions with reduced abuse potential, thereby providing safer options to patients.
H.C. Wainwright & Co. acted as the exclusive placement agent for the warrant exercise offering. The commitment of funds highlights investor interest in Ensysce's innovative approach to reducing the risks associated with opioid use.
